The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism

Type 2 Diabetes Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00558935
• Other study ID #: 24/06
• Status: Terminated
• Phase: N/A
• First received: November 14, 2007
• Last updated: May 9, 2011
• Start date: October 2007
• Est. completion date: December 2008

Study information

• Verified date: May 2011
• Source: Bayside Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of red wine on ABCA1 levels

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: December 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy participants

• Aged 18-65 years

• Free of overt coronary disease

• BMI < 35

• Fasting plasma glucose <6.1 mmol

• Unmedicated

• No major illness

Exclusion Criteria:

• Unable to give informed consent

• Smokers

• Participants with alcoholism

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Heart Disease
• Type 2 Diabetes

Intervention

Dietary Supplement:
• Red Wine
20g alcohol daily/red wine for 4 weeks

Locations

Country	Name	City	State
Australia	Baker Heart Research Institute	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Bayside Health

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	measurements of dyslipidemia		2 years
Secondary	lipid functionality		2 years